iECURE Reports on Preliminary Clinical Response Data in First Infant Dosed with its in vivo Gene Editing Candidate ECUR-506
iECURE reported preliminary findings from the first infant dosed with its in vivo gene editing candidate ECUR-506.
Sahay AI Wins 1682 Venture Award for Most Promising AI-Driven Startups in Philadelphia
Sahay AI won the 1682 Venture Award, a pitch competition for early-stage AI-driven startups based in Philadelphia.
ViTToria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of its VIPER-101 T-Cell Therapy
ViTToria has dosed the first patient in its Phase 1 clinical trial for VIPER-101.
āshibio Moves Forward with Clinical Trial
āshibio announced the dosing of the first participant in its Phase 2/3 clinical trial for its lead candidate, andecaliximab.
Cogwear Featured as a Startup to Watch in 2025
Cogwear was listed as one of PHL Inno’s Startups to Watch.
Interius Ranks in Top Ten of Capital Raises by Philadelphia Startups in 2024
Interius was recognized in the Philadelphia Business Journal’s “PHL Inno 2024 in Review” as one of the top Philadelphia-area startups raising capital last year.
Penn Spinout Gemma Therapeutics Raises $34 million to Develop Gene Therapies for Rare Diseases
Gemma Bio raised $34 million in a seed round led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital.
Mitchell Lab Discovers Siloxane-Enhanced Nanoparticles and Refines LNPs to Advance mRNA Medicine
A group of researchers at Penn Engineering led by Michael Mitchell, PhD, Associate Professor in Bioengineering, have developed a method to direct lipid nanoparticles (LNPs) to target specific tissues.
Franklin Biolabs Names its First CEO
Franklin Biolabs, a Penn spinout founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, has named Vatsala Naageshwaran as its first chief executive officer.
Ocuphire Pharma Announces Acquisition of Opus Genetics, a Penn startup based on technology developed by Dr. Jean Bennett and colleagues
The merger between Opus and Ocuphire creates a transformative biotech company, renamed Opus Genetics, Inc, which is committed to the development of gene therapies for the treatment of IRDs.